GENFIT

GENFIT is a late-stage biopharmaceutical company focused on developing innovative therapeutic and diagnostic solutions for rare and life-threatening liver diseases with high unmet medical needs. They are particularly known for their expertise in Acute-on-Chronic Liver Failure (ACLF) and have a robust pipeline of five assets in development for this condition. Their portfolio also includes programs targeting Cholangiocarcinoma (CCA) and Urea Cycle Disorders (UCD)/Organic Acidemias (OA), along with diagnostic tools for NASH/MASH and ammonia.

GENFIT has a strong track record of success, notably in the development of elafibranor, a dual PPAR a/d agonist for Primary Biliary Cholangitis (PBC). This asset was discovered and successfully developed by GENFIT before being out-licensed to Ipsen for regulatory applications and commercialization. GENFIT has facilities in Lille, Paris, Zurich, and Cambridge, MA, and is publicly traded on both the Nasdaq Global Select Market and Euronext's regulated market in Paris.

GENFIT is a late-stage biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for rare and life-threatening liver diseases with high unmet medical needs. They are a pioneer in their field, with a strong track record of successfully bringing early-stage assets with high potential to late-stage development and commercialization. Their focus is on improving the lives of patients suffering from liver diseases worldwide.

Genfit fosters a culture that values innovation, respect, and ethics. They encourage open communication, collaboration, and a willingness to push boundaries in scientific research. They prioritize diversity and inclusion, valuing different perspectives and experiences, while maintaining a commitment to the highest ethical standards in all aspects of their business. This commitment extends beyond their employees to their interactions with stakeholders, partners, and the broader community.

GENFIT values diversity and inclusion, recognizing it as a strength. They strive to create a workplace where all employees and third parties are treated fairly and with respect. They actively promote a culture of respect, valuing the unique perspectives and experiences of their employees, and ensure equal opportunities for all.